In a surprising turn, Indian drugmakers' shares jumped 5% following the U.S. exempting pharmaceuticals from new tariffs. This decision could significantly boost India's pharma exports, which reached $9 billion last year.
As President Trump prepares to unveil a major tariff plan, pharmaceutical companies are lobbying for a gradual implementation to mitigate the impact on drug prices and supply. With potential tariffs looming, how will the industry adapt?
